

The first-ever PROTAC drug won FDA approval, then its own partners couldn't agree on how to sell it. A three-way deal with Rigel Pharmaceuticals finally resolves months of commercial limbo, and it could set the template for an entire new class of medicines.
Imagine spending years building the first house on Mars, only to realize nobody brought the furniture. That's roughly what happened with Veppanu (vepdegestrant), the first-ever PROTAC drug to win FDA approval. The science was historic. The commercial plan was a mess.
Now, a three-way deal between Arvinas, Pfizer, and Rigel Pharmaceuticals finally sorts it out. But getting here required months of awkward corporate therapy.
Veppanu earned FDA approval on May 1, 2026 for a specific type of advanced breast cancer: ER-positive, HER2-negative tumors carrying ESR1 mutations. These mutations pop up in roughly 40% of patients after treatment with standard hormone-blocking therapies. They help the cancer keep growing even when estrogen is cut off.
PROTACs work differently from traditional drugs. Instead of just blocking a bad protein, they tag it for destruction. Think of it like the difference between putting a boot on a car versus calling a tow truck. Veppanu tags the estrogen receptor for the cell's own recycling system, which chews it up entirely.
In the pivotal VERITAC-2 trial, patients with ESR1 mutations who took Veppanu saw a 43% reduction in the risk of their cancer getting worse, compared to fulvestrant (the old injectable standard). Response rates were nearly five times higher: 19% versus 4%. The science worked.
The business side? Not so much.
Back in July 2021, Arvinas and Pfizer struck a classic big-pharma partnership. They would split everything 50/50: costs, profits, global commercialization. The bet was that Veppanu would become a cornerstone of breast cancer treatment, used broadly across ER-positive disease.
Then the data came in, and reality narrowed the dream.
Veppanu crushed fulvestrant in ESR1-mutated patients, but in the overall trial population (including patients without ESR1 mutations), the benefit essentially vanished. That meant the label would be restricted to the ESR1-mutated subset only, a meaningful but much smaller market than originally envisioned.

A gene-edited pig kidney just kept a man alive and off dialysis for 271 days, shattering every record in xenotransplantation. With FDA approval for an expanded trial in hand, eGenesis is turning science fiction into a real answer for the 90,000 Americans stuck on the kidney transplant waiting list.


Join thousands of biotech professionals who start their day with our free, daily briefing.
By early June 2025, Arvinas CEO John Houston was telling investors the quiet part out loud. The opportunity was "smaller" than expected. It "doesn't move the dial for Pfizer" under a 50/50 structure. And honestly, it wasn't great for Arvinas either; they'd still be on the hook for half the commercial costs in a niche market.
Picture two people who bought a restaurant together expecting it would be the next Cheesecake Factory, then realizing it's more of a beloved neighborhood bistro. Still good! Just not what you architected a partnership around.
On May 12, 2026, Arvinas and Pfizer announced they'd licensed Veppanu's global rights to Rigel Pharmaceuticals. The structure is clean.
Rigel gets: exclusive worldwide rights to develop, manufacture, and sell Veppanu. They run the U.S. launch and can sublicense outside the country.
Arvinas and Pfizer get: $70 million upfront, plus $15 million tied to transition milestones (split evenly between them). On top of that, up to $320 million in future milestone payments and tiered royalties in the mid-teens to mid-twenties percent on net sales. All split 50/50.
Rigel also kicks in up to $40 million over four years toward ongoing development costs, while Arvinas and Pfizer finish their existing clinical work.
Why Rigel? Because what looks like a niche product for Pfizer looks like a flagship for a $275 million revenue company. Rigel already sells three oncology and hematology drugs (Tavalisse, Rezlidhia, and Gavreto) through a specialty sales force that calls on the exact same oncologists who treat breast cancer. For them, adding Veppanu is like a food truck adding a second menu item: same kitchen, same customers, way more revenue.
Rigel has described Veppanu as a major focus to accelerate revenue growth and a meaningful driver of long-term growth.
Veppanu isn't walking into an empty room. The ESR1-mutated breast cancer space has gotten competitive fast.
Elacestrant (Orserdu), approved in early 2023, was the first oral option specifically for ESR1-mutated disease. It got there first, but its efficacy bar is moderate. Then came imlunestrant (Inluriyo) from Eli Lilly, approved in September 2025, which showed a 38% reduction in disease progression risk and comes bundled with an abemaciclib combination strategy. AstraZeneca's camizestrant has Breakthrough Therapy designation and strong Phase 3 data. Roche's giredestrant combined with everolimus showed a striking 62% risk reduction in ESR1-mutated patients.
Veppanu's edge is its mechanism: it's the only PROTAC in the group, degrading the estrogen receptor rather than just blocking it. Whether that translates into a durable commercial advantage will depend on real-world outcomes, combination data, and (frankly) how well Rigel executes the launch.
Forget the specific dollar amounts for a second. The bigger story is what this deal signals for an entire class of drugs.
PROTACs have been the darling of biotech conferences for years, promising to drug the "undruggable" by destroying disease proteins rather than merely inhibiting them. But conference slides don't pay the bills. Commercial proof does.
Veppanu's approval was the scientific milestone. This Rigel deal is the commercial one. It shows that a PROTAC drug can find a viable path to market, even when the initial commercial blueprint falls apart. The template here (platform innovators hand off to specialized commercial partners) could become the default playbook for future degrader drugs.
For Arvinas, the deal also frees up resources and attention for the rest of their PROTAC pipeline. For Pfizer, it clears an awkward line item off the books. And for Rigel, it's a bet-the-company moment disguised as a licensing deal.
The first approved PROTAC nearly stumbled at the finish line, not because the science failed, but because the business model didn't match the market. It took a three-way restructuring and a smaller, hungrier partner to fix it.
The drug works. Now we'll find out if the deal does too.
UCB's Bimzelx just beat AbbVie's Skyrizi in a head-to-head psoriatic arthritis trial, posting the first-ever biologic superiority win on a major joint endpoint. The results could reshape how doctors pick treatments in a $13 billion market.